TY - JOUR
T1 - Analysis of the T-cell repertoire and transcriptome identifies mechanisms of regulatory T-cell suppression of GVHD
AU - Lohmeyer, Juliane K.
AU - Hirai, Toshihito
AU - Turkoz, Mustafa
AU - Buhler, Stephane
AU - Lopes Ramos, Teresa
AU - Köhler, Natalie
AU - Baker, Jeanette
AU - Melotti, Astrid
AU - Wagner, Ingrid
AU - Pradier, Amandine
AU - Wang, Sisi
AU - Ji, Xuhuai
AU - Becattini, Simone
AU - Villard, Jean
AU - Merkler, Doron
AU - Chalandon, Yves
AU - Negrin, Robert S.
AU - Simonetta, Federico
N1 - Funding Information:
This work was supported with funding from National Institutes of Health (NIH), National Cancer Institute grants R01 CA23158201 (R.S.N.) and P01 CA49605 (R.S.N.), the Parker Institute for Cancer Immunotherapy (R.S.N.), G erman Cancer Aid Mildred Scheel Postdoctoral Fellowship (J.K.L.), Swiss Cancer League BIL KLS 3806-02-2016 (F.S.), Geneva Cancer League LGC 20 11 (F.S.), the American Society for Blood and Marrow Transplantation New Investigator Award 2018 (F.S.), Dubois-Ferrière-Dinu-Lipatti Foundation (F.S.), the ChooseLife Foundation (F.S.), Fondation Gustave & Simone Prévot (F.S.), Fondation Henriette Meyer (F.S.), and Gruenewald-Zuberbier Foundation (N.K.). Flow cytometry analysis and sorting were performed on instruments in the Stanford Shared FACS Facility purchased using an S10 Shared Instrumentation Grant from the NIH (S10RR027431-01). Sequencing was performed on instruments in the Stanford Functional Genomics Facility, including the Illumina HiSeq 4000 purchased using an S10 Shared Instrumentation Grant from the NIH (S10OD018220).
Funding Information:
This work was supported with funding from National Institutes of Health (NIH), National Cancer Institute grants R01 CA23158201 (R.S.N.) and P01 CA49605 (R.S.N.), the Parker Institute for Cancer Immunotherapy (R.S.N.), German Cancer Aid Mildred Scheel Postdoctoral Fellowship (J.K.L.), Swiss Cancer League BIL KLS 3806-02-2016 (F.S.), Geneva Cancer League LGC 20 11 (F.S.), the American Society for Blood and Marrow Transplantation New Investigator Award 2018 (F.S.), Dubois-Ferrière-Dinu-Lipatti Foundation (F.S.), the ChooseLife Foundation (F.S.), Fondation Gustave & Simone Prévot (F.S.), Fondation Henriette Meyer (F.S.), and Gruenewald-Zuberbier Foundation (N.K.). Flow cytometry analysis and sorting were performed on instruments in the Stanford Shared FACS Facility purchased using an S10 Shared Instrumentation Grant from the NIH (S10RR027431-01). Sequencing was performed on instruments in the Stanford Functional Genomics Facility, including the Illumina HiSeq 4000 purchased using an S10 Shared Instrumentation Grant from the NIH (S10OD018220). Contribution: J.K.L. T.H. M.T. and F.S. conceived and designed research studies; J.K.L. T.H. M.T. T.L.R. A.M. I.W. A.P. S.W. and F.S. conducted experiments; J.K.L. S. Buhler, N.K. S.W. and F.S. analyzed data; X.J. developed methodology and analyzed data; J.B. developed methodology and provided essential reagents; S. Becattini, J.V. D.M. and Y.C. provided essential tools and intellectual input; J.K.L. F.S. and R.S.N. wrote the manuscript; and F.S. and R.S.N. supervised the research.
Publisher Copyright:
© 2023 The American Society of Hematology
PY - 2023/4/6
Y1 - 2023/4/6
N2 - CD4+FOXP3+ regulatory T cells (Tregs) have demonstrated efficacy in the prevention and treatment of graft-versus-host disease (GVHD). Preclinical and clinical studies indicate that Tregs are able to protect from GVHD without interfering with the graft-versus-tumor (GVT) effect of hematopoietic cell transplantation (HCT), although the underlying molecular mechanisms are largely unknown. To elucidate Treg suppressive function during in vivo suppression of acute GVHD, we performed paired T-cell receptor (TCRα and ΤCRβ genes) repertoire sequencing and RNA sequencing analysis on conventional T cells (Tcons) and Tregs before and after transplantation in a major histocompatibility complex –mismatched mouse model of HCT. We show that both Tregs and Tcons underwent clonal restriction, and Tregs did not interfere with the activation of alloreactive Tcon clones and the breadth of their TCR repertoire but markedly suppressed their expansion. Transcriptomic analysis revealed that Tregs predominantly affected the transcriptome of CD4 Tcons and, to a lesser extent, that of CD8 Tcons, thus modulating the transcription of genes encoding pro- and anti-inflammatory molecules as well as enzymes involved in metabolic processes, inducing a switch from glycolysis to oxidative phosphorylation. Finally, Tregs did not interfere with the induction of gene sets involved in the GVT effect. Our results shed light onto the mechanisms of acute GVHD suppression by Tregs and will support the clinical translation of this immunoregulatory approach.
AB - CD4+FOXP3+ regulatory T cells (Tregs) have demonstrated efficacy in the prevention and treatment of graft-versus-host disease (GVHD). Preclinical and clinical studies indicate that Tregs are able to protect from GVHD without interfering with the graft-versus-tumor (GVT) effect of hematopoietic cell transplantation (HCT), although the underlying molecular mechanisms are largely unknown. To elucidate Treg suppressive function during in vivo suppression of acute GVHD, we performed paired T-cell receptor (TCRα and ΤCRβ genes) repertoire sequencing and RNA sequencing analysis on conventional T cells (Tcons) and Tregs before and after transplantation in a major histocompatibility complex –mismatched mouse model of HCT. We show that both Tregs and Tcons underwent clonal restriction, and Tregs did not interfere with the activation of alloreactive Tcon clones and the breadth of their TCR repertoire but markedly suppressed their expansion. Transcriptomic analysis revealed that Tregs predominantly affected the transcriptome of CD4 Tcons and, to a lesser extent, that of CD8 Tcons, thus modulating the transcription of genes encoding pro- and anti-inflammatory molecules as well as enzymes involved in metabolic processes, inducing a switch from glycolysis to oxidative phosphorylation. Finally, Tregs did not interfere with the induction of gene sets involved in the GVT effect. Our results shed light onto the mechanisms of acute GVHD suppression by Tregs and will support the clinical translation of this immunoregulatory approach.
UR - http://www.scopus.com/inward/record.url?scp=85148740077&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/36574344
U2 - 10.1182/blood.2022017982
DO - 10.1182/blood.2022017982
M3 - Article
C2 - 36574344
AN - SCOPUS:85148740077
SN - 0006-4971
VL - 141
SP - 1755
EP - 1767
JO - Blood
JF - Blood
IS - 14
ER -